TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27194308

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation at 2000 IU
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation at 4000 IU
Number of subjects: 208

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (both doses)
Number of subjects: 208
Study: 24436454

Group type: EXPERIMENTAL
Intervention: Measles vaccine at 4.5 months
Number of subjects: 6417
Study: 22974788

Group type: EXPERIMENTAL
Intervention: Enalapril (ACE inhibitor) for 6 weeks
Number of subjects: 250

Group type: COMPARATOR
Intervention: Control group (normal healthy controls)
Number of subjects: 250
Study: 20303115

Group type: EXPERIMENTAL
Intervention: Amitriptyline (10 to 75 mg once daily over 6 weeks)
Number of subjects: 271

Group type: EXPERIMENTAL
Intervention: Amitriptyline (50 mg or greater)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 271

Group type: COMPARATOR
Intervention: Placebo (for subgroup comparison)
Number of subjects: 271
Study: 18998329

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids therapy (beclomethasone dipropionate or fluticasone propionate)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Montelukast or cromones (Control)
Number of subjects: 109
Study: 15738024

Group type: EXPERIMENTAL
Intervention: Antibiotics effective against Chlamydia (excluded from analysis)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Not applicable (control group of women not receiving antibiotics)
Number of subjects: 140
Study: 12875359

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10642678

Group type: EXPERIMENTAL
Intervention: Oral ivermectin (200 microg/kg body weight)
Number of subjects: 85

Group type: COMPARATOR
Intervention: Topical permethrin cream (5%)
Number of subjects: 85
Study: 8839911

Group type: EXPERIMENTAL
Intervention: EO9 12 mg/m2 weekly (arm A)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: EO9 22 mg/m2 every three weeks (arm B)
Number of subjects: 38
Study: 31251889

Group type: EXPERIMENTAL
Intervention: Training group (n=16) cycled 30 min/day, 3 days/week for 4 weeks at 80% heart rate reserve.
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (n=12) with no training intervention.
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Training group (n=16) and Control group (n=12) both assessed for SS‐FMD.
Number of subjects: 28
Study: 29231263

Group type: EXPERIMENTAL
Intervention: Collagen-stabilized ABBM (test group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: ABBM + autogenous bone (control group)
Number of subjects: 60
Study: 26778544

Group type: EXPERIMENTAL
Intervention: Pomegranate juice (PJ) 200 mL/d for 21 days
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Pomegranate juice diluted 1:1 with water (PJD) 200 mL/d for 21 days
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 31
Study: 24266855

Group type: EXPERIMENTAL
Intervention: Reduced-dose cyclosporine (rCsA) with sirolimus and corticosteroids
Number of subjects: 420

Group type: COMPARATOR
Intervention: Standard-dose cyclosporine (sCsA) with sirolimus and corticosteroids
Number of subjects: 420
Study: 22908696

Group type: EXPERIMENTAL
Intervention: Micronutrient powder (containing iron, folic acid, vitamin C, and zinc)
Number of subjects: 478

Group type: COMPARATOR
Intervention: Iron and folic acid tablets
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Micronutrient powder
Number of subjects: 478

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 478
Study: 18373134

Group type: EXPERIMENTAL
Intervention: EMR‐facilitated disease management in System A
Number of subjects: 12675

Group type: COMPARATOR
Intervention: Patient empowerment interventions in System B
Number of subjects: 12675
Study: 16332466

Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intensive Education Programme (MIEP)
Number of subjects: 99
Study: 14568122

Group type: EXPERIMENTAL
Intervention: Active neuromuscular stimulation for 5 seconds
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Active neuromuscular stimulation for 10 seconds
Number of subjects: 26

Group type: COMPARATOR
Intervention: 0 seconds active neuromuscular stimulation (control group)
Number of subjects: 26
Study: 10632414

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (0.625 mg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 9096964

Group type: EXPERIMENTAL
Intervention: Diet and glyburide (1.25-2.5 mg/day)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Diet alone
Number of subjects: 35
Study: 8237836

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study: 3516511

Group type: EXPERIMENTAL
Intervention: muzolimine, 20 mg/day
Number of subjects: 0

Group type: COMPARATOR
Intervention: hydrochlorothiazide, 50 mg/day and amiloride, 5 mg/day
Number of subjects: 0
Study: 30304013

Group type: EXPERIMENTAL
Intervention: Extended release (ER) onapristone 50 mg BID
Number of subjects: 52

Group type: COMPARATOR
Intervention: Immediate release 100 mg QD
Number of subjects: 52
Study: 26489776

Group type: EXPERIMENTAL
Intervention: Dyadic exercise regimen (individually tailored, for 20-30 min at least five times per week)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 131
Study: 24387919

Group type: EXPERIMENTAL
Intervention: Protocol A - scan delay of 65 s after starting contrast injection over 30 s
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Protocol B - scan delay of 105 s after starting contrast injection over 70 s
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Protocol C - scan delay of 145 s after starting contrast injection over 110 s
Number of subjects: 142
Study: 22705422

Group type: EXPERIMENTAL
Intervention: Hypocaloric energy group (50%-90% of REEm, En-low)
Number of subjects: 33

Group type: COMPARATOR
Intervention: General energy group (90%-130% of REEm, En-gen)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Measured REE (REEm)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Correlation with APACHE II score
Number of subjects: 33
Study: 20178531

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid and cryotherapy
Number of subjects: 0
Study: 18821954

Group type: EXPERIMENTAL
Intervention: Leaflet with basic first aid message regarding tooth avulsion
Number of subjects: 150

Group type: COMPARATOR
Intervention: Control group (no leaflet)
Number of subjects: 150
Study: 16567931

Group type: EXPERIMENTAL
Intervention: Warfarin (adjusted-dose, INR 1.4-2.8)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin (325 mg/day)
Number of subjects: 0
Study: 12587093

Group type: EXPERIMENTAL
Intervention: NRTI therapy
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control (treatment-naive)
Number of subjects: 26
Study: 10879578

Group type: EXPERIMENTAL
Intervention: Psychological treatment (4 sessions of relaxation and stimulus control)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 0
Study: 8792889

Group type: EXPERIMENTAL
Intervention: 20 ml of bupivacaine 2.5 mg/ml with 3 mg of morphine (Group I)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 20 ml of bupivacaine 2.5 mg/ml (Group II)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: 20 ml isotonic saline with 3 mg morphine (Group III)
Number of subjects: 107

Group type: COMPARATOR
Intervention: 20 ml of isotonic saline (placebo, Group IV)
Number of subjects: 107
Study: 1627201

Group type: EXPERIMENTAL
Intervention: sertaconazole 1% cream
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: sertaconazole 2% cream
Number of subjects: 20
Study: 6148873

Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Nadolol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Pindolol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 29602735

Group type: EXPERIMENTAL
Intervention: Standard adjuvant chemotherapy
Number of subjects: 145

Group type: COMPARATOR
Intervention: Capecitabine
Number of subjects: 145
Study: 26976697

Group type: EXPERIMENTAL
Intervention: Surgically supported rapid maxillary expansion (SRME)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Le Fort I osteotomy (LFIO)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Comparison of SRME and LFIO
Number of subjects: 32
Study: 24730623

Group type: EXPERIMENTAL
Intervention: Standard phacoaspiration with PPC and intracameral triamcinolone (Group A)
Number of subjects: 20

Group type: COMPARATOR
Intervention: No triamcinolone used (Group B)
Number of subjects: 20
Study: 23818408

Group type: EXPERIMENTAL
Intervention: Local vibration stimulus training programme
Number of subjects: 31

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 31
Study: 20093373

Group type: EXPERIMENTAL
Intervention: Induced gamma activity at 62 Hz
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Induced gamma activity at 44 Hz
Number of subjects: 0
Study: 18823217

Group type: COMPARATOR
Intervention: Etravirine 100 mg after a fasted state
Number of subjects: 24

Group type: COMPARATOR
Intervention: Etravirine 100 mg after a light breakfast (croissant)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Etravirine 100 mg after an enhanced-fiber breakfast
Number of subjects: 24

Group type: COMPARATOR
Intervention: Etravirine 100 mg after a high-fat breakfast
Number of subjects: 24
Study: 19116438

Group type: EXPERIMENTAL
Intervention: Intermittent hypoxic exposure (5 days/week for 3 weeks)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (ambient air)
Number of subjects: 10
Study: 14724827

Group type: EXPERIMENTAL
Intervention: Lamivudine 100 mg daily 1 week before chemotherapy (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Deferred lamivudine treatment until serological evidence of hepatitis B virus reactivation (group 2)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lamivudine treatment (group 1)
Number of subjects: 30
Study: 11930591

Group type: EXPERIMENTAL
Intervention: Combination therapy with ribavirin and interferon alfa-2b
Number of subjects: 0
Study: 8737099

Group type: EXPERIMENTAL
Intervention: Continuous ST segment monitoring
Number of subjects: 1067
Study: 1426218

Group type: EXPERIMENTAL
Intervention: Nebulized terbutaline
Number of subjects: 23

Group type: COMPARATOR
Intervention: Intravenous terbutaline
Number of subjects: 23
Study: 2861738

Group type: EXPERIMENTAL
Intervention: Carvedilol (25 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31651973

Group type: EXPERIMENTAL
Intervention: Random forest algorithm
Number of subjects: 26525

Group type: EXPERIMENTAL
Intervention: Gradient boosting algorithm
Number of subjects: 26525

Group type: EXPERIMENTAL
Intervention: Logistic regression algorithm
Number of subjects: 26525

Group type: COMPARATOR
Intervention: Logistic regression, gradient boosting, and random forest algorithms
Number of subjects: 26525
Study: 28505955

Group type: EXPERIMENTAL
Intervention: Thrust manipulation targeting the cervicothoracic junction
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Manual stretch of the upper trapezius muscle
Number of subjects: 102

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Thrust manipulation and stretching
Number of subjects: 102
Study: 25280961

Group type: EXPERIMENTAL
Intervention: Loading parameters (weight load size and frequency)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Weight-load speed
Number of subjects: 12
Study: 23404723

Group type: EXPERIMENTAL
Intervention: REAL group (neurofeedback using near-infrared spectroscopy)
Number of subjects: 20

Group type: COMPARATOR
Intervention: SHAM group (irrelevant randomized signals)
Number of subjects: 20
Study: 21792552

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 19365719

Group type: EXPERIMENTAL
Intervention: Telephone coaching intervention by paraprofessionals
Number of subjects: 62

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 62
Study: 16685181

Group type: EXPERIMENTAL
Intervention: Early Intensive Behavioral Treatment (EIBT)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (special education classes)
Number of subjects: 21
Study: 15298879

Group type: EXPERIMENTAL
Intervention: Oxygen and compressed air (AIRc)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Oxygen and nitrous oxide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oxygen and synthetic air (AIRs)
Number of subjects: 0
Study: 11737006

Group type: EXPERIMENTAL
Intervention: Intramuscular needle insertions into six designated trigger points
Number of subjects: 15

Group type: COMPARATOR
Intervention: Subcutaneous insertions (Control)
Number of subjects: 15
Study: 9008270

Group type: EXPERIMENTAL
Intervention: Didanosine (200 mg q 12h) for 3 days, followed by didanosine (200 mg q 12h) and ciprofloxacin (750 mg q 12h) for 3 days, and then another course of didanosine (200 mg q 12h for 3 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Ciprofloxacin (750 mg q 12h) for 3 days, followed by the combination with didanosine, and then ciprofloxacin (750 mg q 12h for 3 days)
Number of subjects: 16
Study: 8353827

Group type: EXPERIMENTAL
Intervention: Levoprotiline (150 mg)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Maprotiline (150 mg)
Number of subjects: 23
Study: 3621988

Group type: EXPERIMENTAL
Intervention: Diflunisal (1000 mg daily)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Naproxen (750 mg daily)
Number of subjects: 50
Study: 30274772

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 7213

Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 7213

Group type: EXPERIMENTAL
Intervention: Anticoagulation (including Rivaroxaban)
Number of subjects: 7213
Study: 27974114

Group type: EXPERIMENTAL
Intervention: Porcine pulmonary surfactant (PS) + budesonide suspension (0.25 mg/kg)
Number of subjects: 70
Study: 24355814

Group type: EXPERIMENTAL
Intervention: Spot-on formulation containing polyunsaturated fatty acids (PUFAs) and essential oils
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study: 23868093

Group type: EXPERIMENTAL
Intervention: Shock-absorbing flooring (8.3-mm thick Tarkett Omnisports EXCEL)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Standard in situ flooring (2-mm)
Number of subjects: 226
Study: 19452177

Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 10
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 20
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 50
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Fluoridated experimental toothpaste with RDA 100
Number of subjects: 80
Study: 19035110

Group type: EXPERIMENTAL
Intervention: Emergency Care Simulator (ECS) combined with Problem-Based Learning (PBL)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Problem-Based Learning (PBL)
Number of subjects: 42
Study: 16839405

Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Lactobacillus GG
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (hydrolysed whey-based formula)
Number of subjects: 50
Study: 14662234

Group type: EXPERIMENTAL
Intervention: CT scan for diagnosing appendicitis
Number of subjects: 0
Study: 10780315

Group type: EXPERIMENTAL
Intervention: Fluvastatin 40 mg + Bezafibrate 400 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Bezafibrate 400 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg + Bezafibrate 400 mg
Number of subjects: 333

Group type: COMPARATOR
Intervention: Fluvastatin 40 mg
Number of subjects: 333

Group type: EXPERIMENTAL
Intervention: Combination therapy (Fluvastatin + Bezafibrate)
Number of subjects: 333
Study: 8842353

Group type: EXPERIMENTAL
Intervention: Probucol
Number of subjects: 303
Study: 1296496

Group type: EXPERIMENTAL
Intervention: Optiray 300 (ioversol)
Number of subjects: 0
Study: 7049586

Group type: EXPERIMENTAL
Intervention: Clenbuterol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Aminophylline
Number of subjects: 47
Study: 31805295

Group type: EXPERIMENTAL
Intervention: Trans-catheter devices for treating tricuspid regurgitation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Innovative trial designs for pivotal randomized trials
Number of subjects: 0
Study: 30486814

Group type: EXPERIMENTAL
Intervention: Tailored nutritional counselling intervention delivered via telephone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tailored nutritional counselling intervention delivered via mobile application
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 26814241

Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection for 14 days (IE-Tr)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection for 14 days (ES-Tr)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (IE-Ctl)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Control group (ES-Ctl)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection (ES-Tr)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection (IE-Tr)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Local methylcobalamin combined with lidocaine injection (IE-Tr and ES-Tr)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Postherpetic neuralgia incidence
Number of subjects: 204
Study: 24411005

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) with 30 seconds exposure duration
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm) with 1 minute exposure duration
Number of subjects: 5
Study: 18444724

Group type: EXPERIMENTAL
Intervention: Comorbid disorders during adolescence
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Internalizing and externalizing disorders
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: More internalizing diagnoses
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: More externalizing disorders
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: More internalizing diagnoses for females
Number of subjects: 80
Study: 15719856

Group type: EXPERIMENTAL
Intervention: 10 cmH2O of PEEP to the dependent lung during one-lung ventilation
Number of subjects: 46

Group type: COMPARATOR
Intervention: Zero end-expiratory pressure (ZEEP)
Number of subjects: 46
Study: 11323542

Group type: EXPERIMENTAL
Intervention: Iron treatment (twice a day ferrous iron, equivalent to 2 x 100 mg elemental iron)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Iron treatment
Number of subjects: 40
Study: 9466092

Group type: EXPERIMENTAL
Intervention: BIPAP
Number of subjects: 596

Group type: COMPARATOR
Intervention: S-CMV
Number of subjects: 596

Group type: COMPARATOR
Intervention: S-IMV
Number of subjects: 596
Study: 8187302

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms s.c.) 12 hours prior to GHRH
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo 12 hours prior to GHRH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms s.c.) 8 hours prior to GHRH
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo 8 hours prior to GHRH
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Octreotide (200 micrograms s.c.) 16 hours prior to GHRH
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo 16 hours prior to GHRH
Number of subjects: 24
Study: 3285832

Group type: EXPERIMENTAL
Intervention: 5 mg torasemide
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 10 mg torasemide
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: 10 mg torasemide (increased to 20 mg)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 111
Study: 11425972

Group type: EXPERIMENTAL
Intervention: Whole-body PET with fluorine 18 alpha-methyl tyrosine (FMT)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Whole-body PET with 2‐[fluorine 18]fluoro‐2‐deoxy‐D‐glucose (FDG)
Number of subjects: 24
Study: 29573269

Group type: EXPERIMENTAL
Intervention: Take-home laparoscopic simulator training program (2015)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Take-home laparoscopic simulator training program (2016)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Take-home laparoscopic simulator training program
Number of subjects: 33
Study: 29432518

Group type: EXPERIMENTAL
Intervention: Biannual structured medication reviews by physician, pharmacist, and nurse.
Number of subjects: 380

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 380
Study: 27094338

Group type: EXPERIMENTAL
Intervention: Empathic skills training message
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Medical/technical skills training message
Number of subjects: 181
Study: 25130998

Group type: EXPERIMENTAL
Intervention: Lapatinib (1500 mg)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg)
Number of subjects: 455

Group type: EXPERIMENTAL
Intervention: Lapatinib plus Trastuzumab (lapatinib 1000 mg, trastuzumab same dose as single agent)
Number of subjects: 455

Group type: COMPARATOR
Intervention: Pathological complete response
Number of subjects: 455
Study: 22720689

Group type: EXPERIMENTAL
Intervention: Single dose of gentamicin in combination with metronidazole 30 to 60 minutes prior to operation
Number of subjects: 490

Group type: COMPARATOR
Intervention: Multiple doses of gentamicin and metronidazole for 24 hours post-operation
Number of subjects: 490
Study: 20441408

Group type: EXPERIMENTAL
Intervention: 17-hydroxyprogesterone caproate (17OHPC)
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 18540851

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 15951466

Group type: EXPERIMENTAL
Intervention: NN414 (0.625-12.5 mg/kg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11823009

Group type: EXPERIMENTAL
Intervention: PBNT with non-rinse conditioner (NRC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Thermocycling regimens
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polished and fractured specimens
Number of subjects: 0